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Abstract
Background: Rifampin is a first line antituberculosis drug active against bacilli in logarithmic and
stationary phase, which interferes with RNA synthesis by binding to bacterial RNA polymerase.
Tubercle bacilli achieve resistance to rifampin by accumulation of mutations in a short-81 bp region
of the rpoB gene. Among many mutations identified in the rpoB gene, few were verified by molecular
genetic methods as responsible for resistance to rifampin (RMP).
Results: In this study eight different mutations identified in an 81 bp section of a "hot spot" region
of the rpoB gene of RMP resistant Mycobacterium tuberculosis clinical strains were evaluated in
respect to drug resistance. It was found that: mutations in positions 526 (H/D), 516 (D/V) and 531
(S/L) result in high level resistance to rifampin; mutations in positions 516 (D/Y), 515 (M/I), 510 (Q/
H) or a double mutation in codons 512 (S/I) and 516 (D/G) relate to low level of resistance. Gene
rpoB carrying mutations in codon 513 (Q/L) introduced into an M. tuberculosis laboratory strain did
not cause resistance to rifampin, however the same gene introduced into two different clinical
strains did, with the level of resistance depending on the host strain.
Conclusion: Mutations in an 81 bp "hot spot" region of the rpoB of M. tuberculosis lead to different
levels of resistance to rifampin. Some mutations in this "hot spot" region of rpoB require a specific
genetic background for the host strain to develop resistance to rifampin. Therefore, the
identification of such mutations in a clinical M. tuberculosis strain is not enough to classify the given
strain as resistant to rifampin.
Background
Tuberculosis (TB) is a devastating infectious disease caus-
ing high mortality and morbidity worldwide with 8 mil-
lion new TB cases and 2–3 million deaths annually. The
situation of TB is made even worse by the rising emer-
gence of drug resistant strains of Mycobacterium tuberculo-
sis. Multi-drug resistant TB (MDR-TB) is defined as
resistant to at least isoniazid (INH) and rifampin (RMP),
the two most active first-line drugs against TB. MDR-TB
treatment takes up to 2 years with second line drugs,
which are expensive and have side effects. In 2006 US
Centers for Disease Control and Prevention (CDC) and
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the World Health Organization (WHO) drew attention to
the emergence of M. tuberculosis with extensive drug resist-
ance to second-line antituberculosis drugs (XDR). XDR-
TB is resistant to at least INH and RMP among the first-
line drugs and to at least one of three injectable second-
line anti-tuberculosis drugs used in TB treatment (capreo-
mycin, kanamycin, amikacin) [1]. Thus, the treatment of
such tuberculosis is becoming seriously limited, some-
times returning TB control to the pre-antibiotic era [1].
Tuberculosis chemotherapy started in 1944, when strep-
tomycin (SM) was administered for the first time to a crit-
ically ill TB patient. Later, TB treatment was enriched with
paraaminosalicylic acid (PAS-1949), INH (1952), pyrazi-
namide (PZA-1954), ethambutol (EMB-1962) and RMP
(1963). It was identified that monotherapy generates
drug-resistant mutants within a few months, endangering
the success of antibiotic treatment. This problem was
overcome by using combinations of drugs with as many as
four drugs recommended nowadays by CDC and WHO
[2].
The key antituberculosis drug commonly used in the treat-
ment of tuberculosis is RMP. The loss of RMP as an effec-
tive drug leads to a need for a longer duration of therapy
and often to a lower cure rate [3-6]. Drug resistance in M.
tuberculosis  is caused by mutations of various chromo-
somal genes, as identified for MDR occurrence due to the
sequential accumulation of mutations in different genes
that provide resistance to individual drugs. The individual
molecular mechanisms of resistance have been identified
for all first-line drugs and the majority of second-line
drugs [7]. In M. tuberculosis, resistance to RMP results from
mutations in the β-subunit of RNA polymerase, which is
encoded by the rpoB gene [8]. Approximately 95% of
RMP-resistant strains carry mutations within an 81-bp
region containing codons 507 through 533 of the rpoB
gene [8-10]. The single mechanism of resistance and nar-
row distribution of mutations make rpoB-81 bp region
very attractive for molecular detection of resistance to
RMP [11,12]. However, within several dozen different
mutations detected in the rpoB-81 bp region of RMP-
resistant M. tuberculosis strains [for review see [13]], very
few were tested by cloning and complementation assays.
Mutated rpoB genes (S531L; H526Y; D516V) were intro-
duced into the RMP sensitive M. tuberculosis H37Rv strain,
resulting in acquired drug resistance of the host strain
[14]. These authors observed that the level of acquired
resistance was higher for mutants carrying mutations in
codons 531 and 526 compared to mutation in codon 516.
In this paper a genetic model was constructed allowing for
a relatively simple verification of the relationship between
the presence of a given mutation in rpoB-81 bp region and
the RMP resistance of the host strain carrying such a muta-
tion. Some rpoB mutations revealed drug-resistance only
in selected M. tuberculosis strains suggesting that genetic
background of the host is important for the development
of resistance to RMP.
Methods
Bacterial strains and growth conditions
The M. tuberculosis strains examined for this study were
isolated from TB patients in Poland in 2000 during the
second national survey of drug resistance [12,15]. Eight
clinical strains identified as drug resistant, carrying differ-
ent mutations in the rpoB  gene, and two susceptible
strains identified as drug sensitive, which did not carry
any mutation in rpoB, were selected. Moreover, a control
laboratory strain M. tuberculosis H37Ra, was included in
this study. Primary isolation, differentiation, and drug
susceptibility testing were performed with Lowenstein-
Jensen (LJ) medium and the BACTEC 460-TB system (Bec-
ton-Dickinson, Sparks, Md.), as reported earlier [15]. All
mycobacterial strains used in this study were cultured in
Middlebrook 7H9 broth supplemented with OADC
(albumin-dextrose-sodium chloride) and with kanamycin
(25 μg/ml), or hygromycin (10 μg/ml), when required.
Mycobacterial transformants were selected on Middle-
brook 7H10 agar plates enriched with OADC containing
kanamycin (Km) or hygromycin (Hyg).
Gene cloning strategies
Standard molecular biology protocols were used for all
cloning procedures [16]. All PCR products were obtained
using thermostable ExTaq polymerase (Takara) and
cloned initially into pGemT vector (Promega), sequenced,
and then released by digestion with appropriate restric-
tion enzymes before cloning into the final vectors. Some
restriction enzymes recognition sites were incorporated
into the sequence of primers. The primers and plasmids
used in this work are listed in Table 1 and 2, respectively.
To engineer various rpoB genes of M. tuberculosis control-
led by a natural promoter, a basal pRpoZero vector was
constructed (Fig. 1). The vector contained the 5' end of
rpoB until a natural BstEII restriction enzyme recognition
site (681 plus 950 bp of upstream region) which was con-
nected to the 3' fragment of the gene starting with a natu-
ral BstEII restriction enzyme recognition site (1122 plus
218 bp of downstream region). The resultant construct
was used for cloning of the inner BstEII-BstEII fragment
(1716 bp) of rpoB genes from various M. tuberculosis clin-
ical strains resistant to RMP. The correct orientation of
cloned  BstEII fragments was verified by digestion with
PvuII endonuclease. Next, the cloned genes controlled by
their natural promoter, carrying given mutations or wild
type sequence in the hot spot region were relocated into
the pMV306 integration vector. The resultant constructs
(pMRP1-9) were electrotransformed into RMP susceptible
strains, and the integration of DNA was monitored by Km
selection and verified by PCR. Alternatively, the investi-
gated  rpoB  genes were relocated without putative pro-BMC Microbiology 2009, 9:10 http://www.biomedcentral.com/1471-2180/9/10
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moter sequence into pMV306Phsp integration vector under
control of strong promoter (Phsp65). The resultant con-
structs (pMHRP1-9) were electrotransformed into RMP
susceptible strains, and the integration of DNA was mon-
itored by Hyg selection and verified by PCR.
Susceptibility testing
Susceptibility testing was conducted using the proportion
method on Youmans' liquid medium supplemented with
10% OADC with seven concentrations of RMP (50, 25,
12.5, 6.2, 1.5, 0.75, 0.37 μg/ml). The growth was deter-
mined after 21 days of incubation. The results were veri-
fied by Alamar Blue Assay [17-19] and by plating bacteria
on Middlebrook 7H10 supplemented with OADC and
various concentrations of RMP.
Results
The level of RMP resistance depends on the site and kind 
of substitution identified in the rpoB gene
The epidemiological studies carried out in many clinical
laboratories worldwide have revealed several dozen muta-
tions present in the rpoB gene of RMP resistant M. tubercu-
losis strains [12,14,20-23]. According to our knowledge,
only three specific mutations of rpoB have been verified so
far by molecular cloning techniques [14]. The comple-
mentation of RMP sensitive M. tuberculosis strain with rpoB
gene carrying given mutation is not simply due to the gene
length (3519 bp). One step amplification of gene together
with its putative promoter based on M. tuberculosis
genomic DNA as a template and its cloning is rather tough
for investigators. To avoid this problem we have engi-
neered pRpoZero vector carrying a 950 bp putative pro-
moter region followed by 5'(721 bp) and 3' (1258 bp)
rpoB gene fragments of an RMP-sensitive M. tuberculosis
H37Ra strain (Fig. 1). The missing inner part of the rpoB
gene flanked with natural BstEII restriction sites contains
an 81-bp mutable region. The BstEII fragment (1716 bp)
of rpoB gene can be easily amplified based on genomic
DNA isolated from investigated M. tuberculosis RMP-resist-
ant strains and cloned in frame to complete the rpoB gene
in the pRpoZero system.
In this study we have selected eight M. tuberculosis RMP-
resistant clinical strains carrying different mutations in
rpoB gene [12] (Table 3). The PCR generated BstEII inner
fragments of the rpoB gene were verified by sequencing
and were cloned into the pRpoZero vector. The correct ori-
entation of insert was confirmed by PvuII restriction anal-
ysis. Subsequently, the constructed genes, together with
Construction strategy of integration (pMRP1-9; pMHRP1-9)  and self-replicating (pMERP1-9) plasmids carrying wild type  and mutated rpoB genes under control of own (pMRP1-9)  and heat shock (pMHRP1-9; pMERP1-9) promoter Figure 1
Construction strategy of integration (pMRP1-9; 
pMHRP1-9) and self-replicating (pMERP1-9) plasmids 
carrying wild type and mutated rpoB genes under 
control of own (pMRP1-9) and heat shock (pMHRP1-
9; pMERP1-9) promoter. Description in the text.
Table 1: Primer sequences used for PCR amplification
Amplified region Primer Sequence Product size (bp)
promoter region (950 bp) and 5' part of rpoB gene (721 bp) P-rpo-s 5'-tctagacgagagcggcggtgcaatc 1671
P-rpo-r 5'-gctcgctggtccagcccagc
3' part of rpoB gene (1258 bp) and downstream region (218 bp) 3'rpo-s 5'-cgacaccaagctgggtgcgg 1476
3'rpo-r 5'-aagcttccagtcgcgagtcggcccg
BstEII fragment of rpoB gene including 81-bp hot spot region bst-s 5'-cgcgacaccgtcggcgtgcg 1852
bst-r 5'-aagtgtcgcgcacctcgcgggc
pMV306 (221 bp) and insert DNA cloned in MCS of this vector MV-r 5'-aaggcccagtctttcgactgagc 221 + insert
MV-s 5'-gtggataaccgtattaccgcc DNABMC Microbiology 2009, 9:10 http://www.biomedcentral.com/1471-2180/9/10
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the putative promoter region, were relocated into the
pMV306 integration vector using XbaI and HindIII restric-
tion enzymes. The resultant constructs carrying wild type
or mutated rpoB  genes under control of a natural pro-
moter, were electroporated into an RMP-sensitive M.
tuberculosis H37Ra host. The integration of plasmid DNA
into the attB site of chromosomal DNA was verified by
PCR using MVs and MVr primers.
The wild type clinical strains and engineered M. tuberculo-
sis H37Ra mutants were subjected to RMP-resistance anal-
ysis using the proportional method. Each strain was
encoded by number and analyzed at least three times by
standard procedure at the National Reference Center for
Mycobacteria in Poland. The results obtained by the pro-
portional method were verified using Alamar Blue Assay
and by plating bacteria on Middebrook 7H10 supple-
mented with OADC and various concentrations of RMP
(data not shown). The results obtained for clinical strains
and engineered mutants are summarized in Table 3 and 4,
respectively. Only three out of eight analyzed mutations
(H526D; D516V; S531L) revealed the same level of RMP-
resistance in clinical strains and engineered H37Ra
mutants. Introduction of other mutations identified in
RMP-resistant  M. tuberculosis clinical strains into the
H37Ra host did not result in resistance to RMP or the level
Table 2: Plasmids used in this study
Plasmid Description Source
Cloning vectors
pGemTEasy T/A cloning Promega
pMV306H mycobacterial integrating vector, HygR Med-Immune Inc.
pMV306K mycobacterial integrating vector, KanR Med-Immune Inc.
pMV261 mycobacterial Escherichia coli shuttle vector, carrying heat shock (Phsp65) promoter, KmR Med-Immune Inc.
RpoB expression vectors
pMRP1 wild type rpoB of M. tuberculosis H37Ra controlled by natural promoter PrpoB cloned in integration vector 
pMV306K, KanR
This study
pMRP2-9 mutated rpoB of M. tuberculosis clinical strains controlled by natural promoter PrpoB cloned in integration vector 
pMV306K; 2-represents H526D; 3-D516V; 4-Q510H/D516Y; 5-S512I/D516G; 6-Q513L; 7-M515I/D516Y; 8-
D516Y; 9-S531L, respectively, KanR
This study
pMERP1 wild type rpoB of M. tuberculosis H37Ra controlled by heat shock promoter Phsp65 in pMV261, KanR This study
pMERP2-9 mutated rpoB of M. tuberculosis clinical strains controlled by heat shock promoter Phsp65 in pMV261, 2-represents 
H526D; 3-D516V; 4-Q510H/D516Y; 5-S512I/D516G; 6-Q513L; 7-M515I/D516Y; 8-D516Y; 9-S531L, 
respectively, KanR
This study
pMHRP1 wild type rpoB of M. tuberculosis H37Ra controlled by heat shock promoter Phsp65 in pMV306, HygR This study
pMHRP2-9 mutated rpoB of M. tuberculosis clinical strains controlled by heat shock promoter Phsp65 in pMV306, '2-represents 
H526D; 3-D516V; 4-Q510H/D516Y; 5-S512I/D516G; 6-Q513L; 7-M515I/D516Y; 8-D516Y; 9-S531L, 
respectively, HygR
This study
Table 3: Rifampin resistance of clinical and control M. tuberculosis strains
M. tuberculosis clinical strains mutated amino acid of RpoB MIC of rifampin ( g/ml)
Mt.2 H526D 25
Mt.3 D516V 25
Mt.4 Q510H; D516Y 25
Mt.5 S512I; D516G 12,5
Mt.6 Q513L 50
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of MIC was very low in comparison with clinical strains.
Mutation of codon 516 substituting D with V resulted in
a high level of RMP resistance. This effect was not
observed when D was substituted with Y or G, even when
an extra mutation was present in codon 510, 512 or 515.
Some rpoB mutations are able to cause RMP resistance 
only in a particular M. tuberculosis host
The observed different levels of resistance of M. tuberculo-
sis clinical strains and H37Ra strain carrying rpoB genes
mutated at the same positions lead to the conclusion that
some mutations in the rpoB gene can reveal drug-resistant
phenotype only in a specific genetic background of the
host. To verify this hypothesis integration vectors carrying
mutated rpoB genes under natural promoters were intro-
duced by electroporation into two M. tuberculosis clinical
strains (KL463; KL1936) sensitive to RMP. The selected
transformants were verified by PCR amplification as
described above. The resultant clinical strains carrying
mutated  rpoB  genes were subjected to RMP resistance
analysis by the proportional method. The results obtained
were compared to the RMP-resistance of clinical strains
carrying the same mutations and to the H37Ra recom-
binants described above (Table 4). The mutated rpoB
genes generating high RMP-resistance level in M. tubercu-
losis H37Ra (H526D; D516V; S531L) were also responsible
for high level of resistance of both clinical strains when
introduced into their chromosomal DNA. On the other
hand, mutation Q513L identified in an M. tuberculosis
strain with resistance to a high level of RMP (MIC up to 50
μg/ml) which did not cause significant resistance of M.
tuberculosis H37Ra (MIC up to 6.2 μg/ml), was responsible
for RMP-resistance of KL463 and KL1936 strains at the
level depending on the host (up to 12.5 and 50 μg/ml,
respectively). The double mutation of rpoB in positions
510 (Q/H) and 516 (D/Y) identified in a highly resistant
M. tuberculosis strain (MIC 25 μg/ml) which did not reveal
resistance in H37Ra (MIC 1.5 μg/ml) was responsible for
low level of resistance of both clinical tubercle bacilli
hosts (MIC 6.2 μg/ml).
The overproduction of mutated RpoB does not cause high 
level of resistance to RMP
We could not exclude that the different resistance of M.
tuberculosis  hosts carrying identical mutations in rpoB
depends on different expression of RpoB controlled by
unknown regulatory proteins. For example, the raised
expression of target molecule (InhA) due to accumula-
tions of mutations in promoter region is one of the
known mechanisms of resistance to INH. As questions
arose as to whether expression of mutated rpoB  genes
under control of the heat shock promoter (Phsp60) resulted
in increased resistance of M. tuberculosis to RMP, the wild
type rpoB and its mutated copies were cloned under con-
trol of the heat shock promoter as described in Methods.
Although we did not have antibodies to test the level of
expression for RpoB, the expression system is known to be
very efficient [24,25]. The self-replicating constructs
(pMERP1-9, Fig. 1) appeared to be very unstable when
introduced into M. tuberculosis host (data not shown).
Therefore the vectors (pMHRP1-9), which are able to inte-
grate into attB site of mycobacterial chromosomal DNA,
carrying wild type and mutated rpoB under Phsp60 promoter
were constructed and electroporated into M. tuberculosis
H37Ra. The presence of the relevant DNA introduced into
the attB site of chromosomal DNA was verified by PCR
amplification. The resultant recombinant strains were
subjected to RMP resistance analysis by the proportional
method. The results of RMP-MIC analysis obtained for
strains carrying mutated rpoB genes under control of the
strong Phsp60 promoter were similar to strains carrying the
same rpoB genes under control of their natural promoter
(Table 4). These observations suggest that the RMP-resist-
ance of M. tuberculosis strains carrying rpoB mutated genes
Table 4: Rifampin resistance of M. tuberculosis recombinant clones
MIC of rifampin ( g/ml) of M. tuberculosis recombinant clones carrying mutated rpoB gene controlled 
by:
mutated amino acid of 
RpoB
PrpoB Phsp65
H37Ra KL1936 KL463 H37Ra
H 5 2 6 D 5 05 05 05 0
D 5 1 6 V 2 52 52 52 5
Q510H; D516Y 1,5 6,2 6,2 6,2
S512I; D516G 6,2 6,2 6,2 6,2
Q513L 6,2 12,5 50 6,2
M515I; D516Y 6,2 6,2 6,2 6,2
D516Y 3,1 6,2 3,1 6,2
S531L 50 50 50 50BMC Microbiology 2009, 9:10 http://www.biomedcentral.com/1471-2180/9/10
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was not dependent on the rpoB  expression level but
resulted from the host genetic background that influence
the drug-resistance phenotype.
Discussion
All bacteria achieve resistance to RMP by mutations in a
defined region of the RNA polymerase subunit β. In M.
tuberculosis, approximately 95% of RMP resistant clinical
isolates carry a mutation in the rpoB gene [8]. On the other
hand, many isolates from M. avium and M. intracellulare
present a natural resistance to RMP as a result of an effi-
cient permeability and exclusion barrier [26,27]. Muta-
tions in rpoB generally result in high level resistance to
RMP. However, specific mutations in codons 511, 516,
518 and 522 can result in a lower resistance to RMP
[14,28,29]. The role of some rpoB  mutations (H526Y,
S531L, D516V) in causing resistance was confirmed by
genetic transformation experiments [14,30]. Several
dozen other mutations identified in the rpoB gene of RMP-
resistant M. tuberculosis clinical isolates have never been
confirmed by genetic cloning [12,31-35]. Nowadays,
when many genetic techniques are well developed, the
knowledge about mutations connected to RMP-resistance
is becoming used in the rapid identification of drug resist-
ance [11,12,36,37]. However, the utility of these tech-
niques depends on the precise information about the role
of any given mutation in RMP resistance.
In this study we have engineered a genetic system which is
helpful in the verification of the relationship between the
presence of a given mutation in rpoB and RMP resistance.
We have found that rpoB gene carrying either D516V or
S531L mutation causes resistance to RMP when intro-
duced into the M. tuberculosis hosts what was in agreement
with previous investigations [14]. On the other hand,
when mutated rpoB was introduced into drug sensitive M.
tuberculosis laboratory or clinical strains, the other substi-
tutions in position 516 (D/Y; D/G), even when supported
with Q510H, M515I or S512I identified in RMP-resistant
M. tuberculosis clinical strains, did not result in a signifi-
cant increase of RMP-resistance. Other authors previously
reported the identification of D516Y substitutions of rpoB
in M. tuberculosis resistance to a high level of RMP [21,38],
low level of RMP [14] and in strains sensitive to RMP [39].
Taken together, this suggests that D516Y/G substitutions
in rpoB are not sufficient to result in RMP-resistance of M.
tuberculosis. The substitutions in codon 526 (H/Y, D, R, L,
P) were usually identified in M. tuberculosis clinical iso-
lates highly resistant to RMP [14,23,38]. In this paper we
have provided direct evidence that mutation H526D in
rpoB is responsible for RMP-resistance when introduced
into M. tuberculosis host. This result is similar to a previous
finding verified by genetic transformation of rpoB carrying
mutation H526Y [14]. By contrast, the contribution of
rpoB carrying Q513L mutation to RMP-resistance was not
that evident. The insertion of this gene into an M. tubercu-
losis H37Ra laboratory strain did not result in a significant
level of RMP-resistance, however the insertion of the same
gene was responsible for resistance to RMP of two M.
tuberculosis clinical strains (MIC 12.5 and 50 μg/ml) when
used as hosts. As identified in various clinical studies, the
level of RMP-resistance of M. tuberculosis isolates carrying
the Q513L mutation varies from 2 to 200 μg/ml
[14,20,21,23,38]. The collected results suggest that rpoB
carrying Q513L mutation is able to cause resistance to
RMP only in selected tubercle bacilli. It is likely that this
mutation can result in RMP-resistance in strains with low
cell wall permeability since this exclusion barrier is
responsible for natural resistance of some MAIC strains
[26,27]. We also cannot exclude the possibility that other
mechanisms support RMP-resistance of strains carrying
Q513L mutation.
The drug resistance of M. tuberculosis can be also con-
nected to the overproduction of a drug target due to accu-
mulation of point mutations in a promoter region [40-
42]. To test whether overproduction of rpoB carrying a
given mutation result in higher MIC for RMP compared to
a strain expressing the same gene under control of the nat-
ural promoter, rpoB genes were cloned under control of
the Phsp promoter and introduced into M. tuberculosis host.
The Phsp promoter, commonly used in genetics studies of
mycobacteria controlling the groEL gene (Rv0440) in M.
tuberculosis, has already been reported as highly active in
mycobacterial cells growing in vitro [24,25]. A recent
microarray study showed that the expression level of groEL
in M. tuberculosis cells growing in log phase is high, but
not higher than rpoB [43]. However, the arresting of M.
tuberculosis growth results in 3.6-fold induction of groEL
with a decrease of rpoB expression in the same conditions
[44]. We have not observed higher RMP resistance when
mutated rpoB genes were expressed under control of Phsp
promoter in comparison to the natural promoter. It is
possible that the natural level of RpoB is high enough to
saturate RMP (if its concentration in cell is low). On the
other hand, the extra expression of rpoB cannot help in
cells accumulating high RMP level. However, to elucidate
this problem an alternative expression system and precise
control of protein expression would be required.
The natural resistance to RMP in some M. avium and M.
intracellulare strains is known to be as a result of an effi-
cient cell wall permeability and exclusion barrier [26,27],
suggesting that these elements may be also important in
M. tuberculosis. Changes in cell wall composition could
affect permeability [45] decreasing the intracellular con-
centration of drug.BMC Microbiology 2009, 9:10 http://www.biomedcentral.com/1471-2180/9/10
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Conclusion
Among several dozen amino acid substitutions identified
in an rpoB 81-bp region only a few are directly responsible
for  M. tuberculosis resistance to rifampin. Many others
require a specific genetic background to develop resist-
ance. Our findings lead to the conclusion that direct,
molecular identification of rifampin resistant M. tubercu-
losis clinical isolates is possible only for strains carrying
selected mutations in RpoB. The identification of other
mutations suggests that investigated strains might be
resistant to this drug.
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